Dec-poc pmpa
CAS: 1422284-17-0
Ref. 3D-XGC28417
| 1mg | A consultar | |
| 5mg | A consultar | |
| 10mg | A consultar | |
| 25mg | A consultar | |
| 50mg | A consultar |
Información del producto
- 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, 1-ethyl 9-(1-Methylethyl) ester, 5-oxide
- 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, 1-ethyl 9-(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1)
Dec-poc pmpa is an oral prodrug that exhibits potent antiviral activity against HIV. It is rapidly converted to its active form, tenofovir alafenamide hemifumarate, in the presence of hydrochloric acid. Dec-poc pmpa has excellent pharmacokinetic properties, resulting in sustained plasma levels and enhanced bioavailability compared to other pharmaceutical preparations of tenofovir. This prodrug undergoes a phase transfer reaction in the body, allowing for efficient conversion to the active antiretroviral agent. Additionally, Dec-poc pmpa has been formulated to minimize impurities and contains an acid-binding agent to reduce potential renal biomarkers associated with tenofovir administration. Its mechanism of action involves inhibiting viral replication by targeting adenine residues in viral DNA synthesis.
Propiedades químicas
Consulta técnica sobre: 3D-XGC28417 Dec-poc pmpa
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
